DBV Technologies S.A. (DBVT) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Surrozen (SRZN) has outperformed DBV Technologies S.A. (DBVT) over the past year, gaining 115.6% versus a loss of 34.4%. Over five years, DBVT leads with a +50.3% price change compared with -79.0% for SRZN. Surrozen is the larger company by market cap ($596.4 million vs $566.8 million), about 1.1 times the size, while DBV Technologies S.A. is growing revenue faster (+35.8% vs -67.4%).
DBV Technologies S.A. converts more of its revenue into profit, with a net margin of -2607.3% versus -6960.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | SRZN |
|---|---|---|
| Share price | $9.02 | $28.46 |
| Market cap | $566.82M | $596.40M |
| 1-day change | -4.25% | -7.21% |
| YTD return | -52.95% | +25.93% |
| 1-year return | -34.40% | +115.61% |
| 5-year return | +50.33% | -78.97% |
| EPS (TTM) | $-3.00 | $-41.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.64M | $3.48M |
| Revenue growth (YoY) | +35.77% | -67.37% |
| Net income (latest FY) | $-146.95M | $-242.03M |
| Operating margin | -2609.23% | -1210.58% |
| Net margin | -2607.29% | -6960.77% |
| 52-week high | $26.19 | $37.83 |
| 52-week low | $8.63 | $12.79 |
| Distance from 52-week high | -65.55% | -24.77% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +305.10% | +123.12% |
| Average volume | 352.88K | 537.16K |
| Shares outstanding | 62.84M | 20.96M |
| Employees | 179 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed DBVT by 150.0 percentage points over the past year.
- DBV Technologies S.A. is more profitable, keeping -2607.3 cents of every revenue dollar as net income versus -6960.8 cents for Surrozen.
- DBV Technologies S.A. grew revenue faster in its latest fiscal year (+35.77% vs -67.37%).
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 179 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
DBVT vs SRZN FAQ
Which is bigger, DBV Technologies S.A. or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $596.40M compared with $566.82M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, DBVT or SRZN?
SRZN returned +115.61% over the past 12 months, compared with -34.40% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.